Clamoxyquin

Summary

Clamoxyquin (CHEMBL2110791) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Chemistry: 321.8 Da · C17H24ClN3O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2110791
Name	Clamoxyquin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	18029
Molecular formula	C17H24ClN3O
Molecular weight	321.8
InChIKey	HOFHLRCDGWSLHX-UHFFFAOYSA-N

SMILES: CCN(CC)CCCNCC1=CC(=C2C=CC=NC2=C1O)Cl

IUPAC name: 5-chloro-7-[[3-(diethylamino)propylamino]methyl]quinolin-8-ol

Also known as: Clamoxiquina, Clamoxyquine, CLAMOXYQUIN

Parent form; salt/anhydrous children: CHEMBL2106065

Patent coverage: 13 distinct patent families (39 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 36 (92%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).